Daniel Joshua Drucker

Daniel J. Drucker is a University Professor of Medicine at the University of Toronto and Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health. His groundbreaking research focuses on glucagon-like peptides (GLP-1 and GLP-2), revolutionizing treatments for diabetes, obesity, and intestinal failure. He discovered GLP-1's roles in insulin secretion, cardioprotection, and inflammation reduction, and GLP-2's application in short bowel syndrome therapy.

Education:

• MD, University of Toronto (1980)
• Internship at Johns Hopkins Hospital
• Residencies in Internal Medicine and Endocrinology at University of Toronto

Research Interests: Drucker's work spans incretin biology, gut hormone therapeutics, metabolic regulation, and inflammation control. His discoveries enabled GLP-1 receptor agonists (e.g., exenatide) and DPP-4 inhibitors for diabetes, along with teduglutide for intestinal failure. Recent studies explore GLP-1's anti-inflammatory actions and cardiometabolic protection.

Awards and Honors:

• Wolf Prize in Medicine (2023)
• Breakthrough Prize in Life Sciences (2025)
• Canada Gairdner International Award (2021)
• Fellow of the Royal Society (2015)
• Princess of Asturias Award (2024)
• Time100 Most Influential People (2024)

Leadership: Holds the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. His lab at Lunenfeld-Tanenbaum Research Institute drives innovation in peptide therapeutics.